Co-Authors
This is a "connection" page, showing publications co-authored by Roberto Caporali and Piercarlo Sarzi-Puttini.
Connection Strength
1.522
-
Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clin Exp Rheumatol. 2021 May-Jun; 39(3):695.
Score: 0.233
-
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021 01; 116:102545.
Score: 0.226
-
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? Autoimmun Rev. 2018 Jan; 17(1):24-28.
Score: 0.185
-
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):804-809.
Score: 0.182
-
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):660-665.
Score: 0.179
-
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):919-928.
Score: 0.179
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.175
-
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol. 2016 05; 43(5):869-74.
Score: 0.164